Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy-Reference-Cited by-同舟云学术

Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy

Published:2024-03-29 Issue:7 Volume:67 Page:5333-5350
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lu Dong¹,Chen Jianwei¹,Qin Li²,Bijou Imani¹,Yi Ping³⁴,Li Feng³⁵,Song Xianzhou¹,MacKenzie Kevin R.³⁵^ORCID,Yu Xin¹,Yang Bin¹,Roy Chowdhury Sandipan¹,Korp James D.⁶,O’Malley Bert W.²,Lonard David M.²,Wang Jin¹²^ORCID

Affiliation:

1. Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States

2. Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, United States

3. Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, United States

4. Department of Biology and Biochemistry, University of Houston, Houston, Texas 77205, United States

5. Center for Drug Discovery, Baylor College of Medicine, Houston, Texas 77030, United States

6. Department of Chemistry, University of Houston, Houston, Texas 77204, United States

Funder

National Cancer Institute

National Institute of Child Health and Human Development

Adrienne Helis Malvin Medical Research Foundation

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01596

Reference44 articles.

1. Nuclear receptor coregulators: modulators of pathology and therapeutic targets

2. The Expanding Cosmos of Nuclear Receptor Coactivators

3. Nuclear Receptor Coactivators: Structural and Functional Biochemistry

4. IκB Kinase α-Mediated Derepression of SMRT Potentiates Acetylation of RelA/p65 by p300

5. The Transcriptional Co-activator p/CIP (NCoA-3) Is Up-regulated by STAT6 and Serves as a Positive Regulator of Transcriptional Activation by STAT6